Literature DB >> 1328283

Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150.

V A Sundqvist1, W Xu, B Wahren.   

Abstract

We have identified antigenic regions within phosphoprotein 150 of human cytomegalovirus (CMV pp150) to which seroreactivity appears in patients with active CMV infection or persists in seropositive persons. A range of 8.3 to 61.6% of healthy CMV-seropositive blood donors were immunoglobulin G positive for single peptides, while 91.6% reacted to a mixture of four peptides. All convalescent-phase serum samples from 26 patients with active CMV infection reacted with either of two peptides encompassing amino acids (aa) 594 to 623 and aa 614 to 643. Patients with a primary CMV infection had patterns of reactivity to single peptides different from those of patients with reactivated CMV infection. The immunoglobulin M antibodies reacted preferentially with the peptides encompassing aa 594 to 663 of CMV pp150.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328283      PMCID: PMC270511          DOI: 10.1128/jcm.30.10.2735-2739.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Large-scale screening of human sera with cytomegalovirus recombinant antigens.

Authors:  M P Landini; M X Guan; G Jahn; W Lindenmaier; M Mach; A Ripalti; A Necker; T Lazzarotto; B Plachter
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

2.  Cloning and characterization of major antigenic determinants of human cytomegalovirus Ad169 seen by the human immune system.

Authors:  W Lindenmaier; A Necker; S Krause; R Bonewald; J Collins
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

4.  Characterization of a major antigenic region on gp55 of human cytomegalovirus.

Authors:  M Silvestri; V A Sundqvist; U Rudén; B Wahren
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

5.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties.

Authors:  G Jahn; B C Scholl; B Traupe; B Fleckenstein
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

7.  Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.

Authors:  P J Converse; T E Fehniger; A Ehrnst; O Strannegård; S Britton
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

8.  Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity.

Authors:  N K Blackburn; T G Besselaar; B D Schoub; K F O'Connell
Journal:  J Med Virol       Date:  1991-01       Impact factor: 2.327

9.  Prokaryotic expression of immunogenic polypeptides of the large phosphoprotein (pp150) of human cytomegalovirus.

Authors:  B C Scholl; J Von Hintzenstern; B Borisch; B Traupe; M Bröker; G Jahn
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

Review 10.  Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.

Authors:  M A Jacobson; J Mills
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

View more
  1 in total

1.  Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens.

Authors:  R Vornhagen; B Plachter; W Hinderer; T H The; J Van Zanten; L Matter; C A Schmidt; H H Sonneborn; G Jahn
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.